728 related articles for article (PubMed ID: 16250828)
1. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
[TBL] [Abstract][Full Text] [Related]
2. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
Denkberg G; Reiter Y
Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
[TBL] [Abstract][Full Text] [Related]
3. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
[TBL] [Abstract][Full Text] [Related]
4. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
6. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
7. T-cell-receptor-like antibodies - generation, function and applications.
Dahan R; Reiter Y
Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
[TBL] [Abstract][Full Text] [Related]
8. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
9. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
10. Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy.
Engberg J; Krogsgaard M; Fugger L
Immunotechnology; 1999 Mar; 4(3-4):273-8. PubMed ID: 10231096
[TBL] [Abstract][Full Text] [Related]
11. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
Haque A; Blum JS
J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623
[TBL] [Abstract][Full Text] [Related]
12. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
[TBL] [Abstract][Full Text] [Related]
13. Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands.
Crawford F; Jordan KR; Stadinski B; Wang Y; Huseby E; Marrack P; Slansky JE; Kappler JW
Immunol Rev; 2006 Apr; 210():156-70. PubMed ID: 16623770
[TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility complex and T cell receptor interaction of the P91A tum- peptide.
McCormick D; Stauss HJ; Thorpe C; Travers P; Dyson PJ
Eur J Immunol; 1996 Dec; 26(12):2895-902. PubMed ID: 8977283
[TBL] [Abstract][Full Text] [Related]
15. [Advances in the study of molecular mechanisms, applications and screening for altered peptide ligand].
Wang QQ; Yang HZ; Hu ZW
Yao Xue Xue Bao; 2008 Feb; 43(2):113-7. PubMed ID: 18507334
[TBL] [Abstract][Full Text] [Related]
16. Structural implications for the design of molecular vaccines.
Apostolopoulos V; Yu M; McKenzie IF; Wilson IA
Curr Opin Mol Ther; 2000 Feb; 2(1):29-36. PubMed ID: 11249650
[TBL] [Abstract][Full Text] [Related]
17. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
18. Neurological autoimmune disease and the trimolecular complex of T-lymphocytes.
Hohlfeld R
Ann Neurol; 1989 Jun; 25(6):531-8. PubMed ID: 2662895
[TBL] [Abstract][Full Text] [Related]
19. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
20. Interactions between CD8alphabeta and the TCRalphabeta/CD3-receptor complex.
Rubin B; Riond J; Leghait J; Gairin JE
Scand J Immunol; 2006 Sep; 64(3):260-70. PubMed ID: 16918695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
